A 12-month double-blind, double-dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort pMDI 2 x 160/4.5 microg bid and 2 x 80/4.5 microg bid compared to formoterol Turbuhaler 2 x 4.5 microg bid and placebo in patients with COPD

Trial Profile

A 12-month double-blind, double-dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort pMDI 2 x 160/4.5 microg bid and 2 x 80/4.5 microg bid compared to formoterol Turbuhaler 2 x 4.5 microg bid and placebo in patients with COPD

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Budesonide/formoterol; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SUN
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 May 2011 Results relating to gene polymorphisms presented at the 107th International Conference of the American Thoracic Society.
    • 03 Nov 2010 Bone mineral density results in a subgroup of patients with moderate to very severe disease have been presented at the 76th Annual Meeting of the American College of Chest Physicians: Chest 2010.
    • 20 May 2009 COPD exacerbation results reported at the 105th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top